reports
DBV Technologies Announces First Subject Screened in COMFORT Toddlers ...
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been act...
DBV Technologies annonce le screening du premier sujet de l'étude comp...
DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Châtillon, France, le 25 juin (22 :30 CEST) 2025 DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Screening du premier sujet à l'Institut de recherche en médecine respiratoire du Michigan, sous la direction du Dr Jeffrey Leflein, investigateur principal.D'autres sites ont été activés et prévoient des...
Novartis AG: 1 director
A director at Novartis AG sold 4,400 shares at 96.069CHF and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- Christian Arnold
- Tobias Fahrenholz
LHN HOLCIM AG
CLN CLARIANT AG
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
IDL ID LOGISTICS GROUP
ARYN ARYZTA AG
ITP INTERPARFUMS
NESN NESTLE S.A.
BEN BENETEAU SA
OERL OC OERLIKON CORPORATION AG
GEBN GEBERIT AG
BAS BASF SE
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
FLU FLUGHAFEN WIEN AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
SIK SIKA AG
MEDCL MEDINCELL SA
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
SFZN SIEGFRIED HOLDING AG
- Christian Arnold
- Tobias Fahrenholz
LHN HOLCIM AG
FME FRESENIUS MEDICAL CARE AG
CLN CLARIANT AG
BVI BUREAU VERITAS SA
ROG ROCHE HOLDING LTD
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
ARYN ARYZTA AG
NESN NESTLE S.A.
OERL OC OERLIKON CORPORATION AG
REE RED ELECTRICA CORP. SA
GEBN GEBERIT AG
BAS BASF SE
SAN SANOFI
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
LPP LPP S.A.
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
SIK SIKA AG
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
GSK GSK PLC
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
NOVO B NOVO NORDISK A/S
SFZN SIEGFRIED HOLDING AG
- Christian Arnold
- Tobias Fahrenholz
LHN HOLCIM AG
CLN CLARIANT AG
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
IDL ID LOGISTICS GROUP
ARYN ARYZTA AG
ITP INTERPARFUMS
NESN NESTLE S.A.
BEN BENETEAU SA
OERL OC OERLIKON CORPORATION AG
GEBN GEBERIT AG
BAS BASF SE
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
FLU FLUGHAFEN WIEN AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
SIK SIKA AG
MEDCL MEDINCELL SA
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
SFZN SIEGFRIED HOLDING AG
- Christian Arnold
- Tobias Fahrenholz
LHN HOLCIM AG
FME FRESENIUS MEDICAL CARE AG
CLN CLARIANT AG
BVI BUREAU VERITAS SA
ROG ROCHE HOLDING LTD
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
ARYN ARYZTA AG
NESN NESTLE S.A.
OERL OC OERLIKON CORPORATION AG
REE RED ELECTRICA CORP. SA
GEBN GEBERIT AG
BAS BASF SE
SAN SANOFI
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
LPP LPP S.A.
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
SIK SIKA AG
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
GSK GSK PLC
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
NOVO B NOVO NORDISK A/S
SFZN SIEGFRIED HOLDING AG
- Christian Arnold
- Tobias Fahrenholz
ODDO : Swiss Equities Conference Feedback – Difficult Q2 but some H2 2...
ODDO BHF and Commerzbank jointly hosted the Swiss Equities Conference in Interlaken, Switzerland, from 10 to 12 June 2025. The event was attended by 64 companies (out of which 59 are listed, and with BASF one non-Swiss company). Some 125 investors met mostly (85%) C-level management in 440 meetings (one-on-one, one-to-few) and plenary sessions, resulting in some 1,100 interactions. Based on our positive assessments for Q2 & H2 2025 as well as beyond, we would like to highlight Accelleron (poten...
LHN HOLCIM AG
CLN CLARIANT AG
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
ARYN ARYZTA AG
NESN NESTLE S.A.
OERL OC OERLIKON CORPORATION AG
GEBN GEBERIT AG
BAS BASF SE
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
SIK SIKA AG
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
SFZN SIEGFRIED HOLDING AG
- Team Pharma
- Team Pharma
DBV Technologies to Participate in Upcoming EAACI Congress 2025
DBV Technologies to Participate in Upcoming EAACI Congress 2025 Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presen...
DBV Technologies participera au prochain congrès EAACI 2025
DBV Technologies participera au prochain congrès EAACI 2025 Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une société biopharmaceutique en phase clinique, annonce aujourd'hui sa participation au congrès European Academy of Allergy and Clinical Immunology (EAACI) qui se tiendra du 13 au 16 juin 2025 à Glasgow, au Royaume-Uni. DBV présentera deux posters, organisera un symposium et tiendra un stand dans le hall d'exposition d...
DBV Technologies Announces the Voting Results of its 2025 Combined Gen...
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by t...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Châtillon, France, le 11 juin 2025 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en phase clinique, a tenu son Assemblée Générale Mixte (l’« Assemblée Générale »). L’Assemblée Générale s’est déroulée au siège social de la Société, sous la présidence de Michel de Rosen, Président du C...
- Pierre FerraguÊ
Information Regarding the Total Number of Voting Rights and Total Numb...
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025 Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights05/30/2025136,973,697Total gross of voting rights: 136,973,697Total net* of voting rights: 136,738,528 * Net to...
Information relative au nombre total des droits de vote et d’actions ...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 001041734...
Roche Holding AG: 1 director
A director at Roche Holding AG sold 2,513 shares at 285.473CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
DBV Technologies announces the filing of an addendum to the 2024 Unive...
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). This Addendum provides an update to t...
DBV Technologies publie un amendement à son Document d’enregistrement ...
DBV Technologies publie un amendement à son Document d’enregistrement universel 2024 Châtillon, France, le 3 juin 2025 DBV Technologies publie un amendement à son Document d’enregistrement universel 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en phase clinique, annonce le dépôt auprès de l’Autorité des marchés financiers (« AMF ») et la mise à disposition auprès du public d’un amendement à son Document d’enregistrement universel 2024 (« l’Amendement »). Cet Amendement intègre notamment une mise à...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.